Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. (Record no. 27388361)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02068 a2200589 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517164149.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201709s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1474-5488 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1016/S1470-2045(17)30446-1 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Maio, Michele |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20170925 |
| 245 00 - TITLE STATEMENT | |
| Title | Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | The Lancet. Oncology |
| Date of publication, distribution, etc. | 09 2017 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1261-1273 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antibodies, Monoclonal, Humanized |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Disease-Free Survival |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Double-Blind Method |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Lung Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Mesothelioma |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Mesothelioma, Malignant |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Response Evaluation Criteria in Solid Tumors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Survival Rate |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Treatment Outcome |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Scherpereel, Arnaud |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Calabrò, Luana |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Aerts, Joachim |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Perez, Susana Cedres |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bearz, Alessandra |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Nackaerts, Kristiaan |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fennell, Dean A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kowalski, Dariusz |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tsao, Anne S |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Taylor, Paul |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Grosso, Federica |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Antonia, Scott J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Nowak, Anna K |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Taboada, Maria |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Puglisi, Martina |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Stockman, Paul K |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kindler, Hedy L |
| 773 0# - HOST ITEM ENTRY | |
| Title | The Lancet. Oncology |
| Related parts | vol. 18 |
| -- | no. 9 |
| -- | p. 1261-1273 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1016/S1470-2045(17)30446-1">https://doi.org/10.1016/S1470-2045(17)30446-1</a> |
| Public note | Available from publisher's website |
No items available.